Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Care Reform's Pricing Impact: 340B Purchasers See Initial 10% Decline in Brand Prices

This article was originally published in RPM Report

Executive Summary

How big an impact do the new Medicaid rebate rules have on prices? There's now way to tell for sure, but prices files analyzed for the 340B program offer a pretty good clue.

You may also be interested in...



Pharma's Stake In Essential Health Benefits

The health reform law lists prescription drugs as one of the 10 categories that plans must include as essential benefits. Decisions on which medicines, how many, and, perhaps most importantly, at what cost to the patient are all questions that HHS needs to determine.

340B: A Test Market for Health Care Reform?

The 340B program got a lot of attention from pharmaceutical industry lobbyists during the health care reform debate. Now it may be getting more attention from the commercial side of the business. Expanded discounts remains a legislative threat—but increased sales to “safety net” purchasers is also a business opportunity.

340B: A Test Market for Health Care Reform?

The 340B program got a lot of attention from pharmaceutical industry lobbyists during the health care reform debate. Now it may be getting more attention from the commercial side of the business. Expanded discounts remains a legislative threat—but increased sales to “safety net” purchasers is also a business opportunity.

Topics

UsernamePublicRestriction

Register

PS080723

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel